Report reveals more investment in digital apps, but slower uptake

25 July 2017

A new report into the use of digital technology by the pharmaceutical industry details increased production of mobile apps, but stagnation in the growth of app downloads.

The document, produced by market intelligence firm Deloitte, includes some primary research on apps developed by 12 major pharma companies and a survey of 190 patient groups for their views on the use of health apps in general, and those developed by pharma.

It finds that, over the past four years, the top 12 pharma companies have more than trebled the number of mobile apps they have commissioned, from 305 in 2013 to 1,060 in early 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK